• No se han encontrado resultados

La tuberculosis en la era del tratamiento con fármacos inhibidores del factor de necrosis tumoral alfa: ¿por qué persiste el riesgo?

N/A
N/A
Protected

Academic year: 2020

Share "La tuberculosis en la era del tratamiento con fármacos inhibidores del factor de necrosis tumoral alfa: ¿por qué persiste el riesgo?"

Copied!
10
0
0

Texto completo

Loading

Referencias

Documento similar

La determinación analítica de anti-TNF se solicitó en la mayoría de casos de forma reactiva, evidenciándose un por- centaje considerable de pacientes que presentan concen-

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in

The analysis of low-frequency genetic variants mapping to the TNF signaling pathway using the SKAT-O test showed that the damaging burden is different between anti-TNF

Teniendo en cuenta que la tuberculosis es una enfermedad infecciosa que persiste en el tiempo como uno de los mayores problemas de salud pública, por el número de casos nuevos

tuberculosis adaptation to a fatty acid environment, we developed an in vitro model where bacilli were grown in even-length long-chain fatty acids (LC-FAs) as the sole carbon

Conversely, the evaluation of mRNA levels of genes encoding pro-in flammatory cytokines [interleukin-1 beta (IL-1 b ), tumor necrosis factor alpha (TNF a ), and transforming

The relationship between the coverage obtained using IS-seq (reads per RFLP band) and the difference be- tween observed and expected sites showed that our method was prone to

Fortunately, physicians appear to be aware of the need to monitor CVD risk in patients with active RA: a study of 14,503 patients in world-wide data from the SUrvey of